We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+31.13%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.73B
AUM Growth
+$575M
Cap. Flow
-$186M
Cap. Flow %
-3.94%
Top 10 Hldgs %
46.08%
Holding
127
New
17
Increased
23
Reduced
25
Closed
19

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$95.5M
2
VKTX icon
Viking Therapeutics
VKTX
+$57.4M
3
ARGX icon
argenx
ARGX
+$52.2M
4
ADGM
Adagio Medical Holdings
ADGM
+$46.7M
5
ORKA
Oruka Therapeutics
ORKA
+$43M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$441M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$60M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$38.8M
5
SWTX
SpringWorks Therapeutics
SWTX
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OBIO icon
51
Orchestra BioMed
OBIO
$322M
$23.6M 0.5%
4,592,556
+2,046,675
+80% +$13.4M
TIL icon
52
Instil Bio
TIL
$51.5M
$23.3M 0.49%
+345,545
New +$8.14M
LIVN icon
53
LivaNova
LIVN
$4.37B
$22.5M 0.48%
429,000
-15,000
-3% -$744K
SWTX
54
DELISTED
SpringWorks Therapeutics
SWTX
$22.2M 0.47%
692,263
-960,699
-58% -$35.9M
MDT icon
55
Medtronic
MDT
$117B
$22.1M 0.47%
245,332
-245,333
-50% -$20.6M
ADMA icon
56
ADMA Biologics
ADMA
$2.18B
$21.2M 0.45%
1,060,200
-1,710,800
-62% -$26.6M
XENE icon
57
Xenon Pharmaceuticals
XENE
$5.85B
$20.7M 0.44%
524,930
-58,326
-10% -$2.35M
ZBIO
58
Zenas BioPharma
ZBIO
$2.2B
$19.4M 0.41%
+1,144,035
New +$20.6M
IRON icon
59
Disc Medicine
IRON
$3.16B
$19M 0.4%
387,017
-166,420
-30% -$7.81M
RCKT icon
60
Rocket Pharmaceuticals
RCKT
$415M
$17.2M 0.36%
931,851
-314,746
-25% -$6.45M
INBX icon
61
Inhibrx
INBX
$1.81B
$16.7M 0.35%
1,064,026
– –
RAPP
62
Rapport Therapeutics
RAPP
$2.46B
$15.3M 0.32%
748,183
– –
MRUS
63
DELISTED
Merus
MRUS
$15M 0.32%
300,000
– –
INSM icon
64
Insmed
INSM
$27.1B
$13.1M 0.28%
180,000
– –
ICLR icon
65
Icon
ICLR
$13B
$12.7M 0.27%
44,353
+13,103
+42% +$4.13M
ARQT icon
66
Arcutis Biotherapeutics
ARQT
$3.12B
$12.6M 0.27%
1,358,500
-200,000
-13% -$1.97M
PEPG icon
67
PepGen
PEPG
$237M
$12.1M 0.26%
1,410,438
– –
TYRA icon
68
Tyra Biosciences
TYRA
$1.59B
$12M 0.25%
511,226
-496,141
-49% -$10.4M
XNCR icon
69
Xencor
XNCR
$2.18B
$10.6M 0.22%
+527,671
New +$9.91M
VRCA icon
70
Verrica Pharmaceuticals
VRCA
$84.9M
$10.3M 0.22%
709,918
– –
ROIV icon
71
Roivant Sciences
ROIV
$26.3B
$9.78M 0.21%
+847,745
New +$9.65M
AVBP icon
72
ArriVent BioPharma
AVBP
$1.55B
$9.75M 0.21%
415,000
– –
EXAS
73
DELISTED
Exact Sciences
EXAS
$8.52M 0.18%
+125,000
New +$7.05M
EYPT icon
74
EyePoint Inc
EYPT
$431M
$8.29M 0.18%
1,037,274
+397,000
+62% +$3.49M
ALLO icon
75
Allogene Therapeutics
ALLO
$750M
$7.63M 0.16%
2,725,000
– –
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Perceptive Advisors held 127 positions worth $4.73B, up 14% from $4.15B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $186M in Q3 2024, closing 19 positions and reducing 25 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $441M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Adagio Medical Holdings worth $25.3M.

  • Perceptive Advisors's largest Q3 2024 buy was Adagio Medical Holdings: 9,812,419 shares worth $25.3M.
  • Perceptive Advisors added most to Verona Pharma in Q3 2024, an estimated $95.5M increase.
  • Perceptive Advisors's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $60M.
  • Perceptive Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $441M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $4.73B portfolio in Q3 2024.
  • Perceptive Advisors opened 17 new positions and closed 19 in Q3 2024.
  • Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $4.73B.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.